Merck announced it is discontinuing all research operations in the United Kingdom and scrapping plans for a £1 billion London drug research center. The decision reflects frustration over lack of meaningful progress in UK government life science investments and policies, including medicine pricing schemes. This move signals broader concerns among pharmaceutical companies about the UK’s competitiveness as a research hub, potentially reshaping future investment and innovation landscapes.